Save the Antibiotic Xenleta as a Last Resort

October 2019

Xenleta (zen-LEH-tah, lefamulin) will be the first oral and IV med in a new class of "pleuromutilin" antibiotics.

Xenleta is approved for community-acquired pneumonia. It will be touted as an option for resistant infections due to its unique mechanism.

But Xenleta doesn't seem more effective than other antibiotics.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote